Articles related to COGNITIVE HEALTH/MEMORY

Unveiling the Secret to Superior Cognitive Health in the Oldest-Old In a breakthrough research, an understanding of the resistance of certain 90+ individuals to neurodegenerative pathologies leading to superior cognitive abilities emerges, presenting avenues for preserving cognitive health in advanced ages. Key Points: “There are some individuals who can maintain high levels of cognitive function well into advanced ages. Further research into the factors that enable these individuals to maintain their cognitive function could provide insights into how to preserve cognitive health despite advanced age.” María M. Corrada, ScD, co-principal investigator of the study

Understanding COVID-19’s Cognitive Effects on College Students As physicians, understanding the cognitive effects of the COVID-19 pandemic on our younger population is crucial. This summary distills key findings from a recent study conducted by The Ohio State University.

Diving into intensive systolic BP treatment unveils intriguing cognitive benefits according to a secondary analysis of the SPRINT trial. The SPRINT trial has shed fresh light on the impact of intensive systolic blood pressure (SBP) treatment on cognitive health. Out of 7,918 participants, a significant majority with higher baseline risk of dementia or mild cognitive impairment (MCI) revealed marked cognitive improvements with intensive SBP treatment. This marks a leap forward in understanding SBP treatment’s role in cognitive function preservation. In the comprehensive secondary analysis, patients were meticulously followed up over a median of four years. To streamline the study, two SBP treatment targets were identified: intensive, set at less than 120 mm Hg, and standard, at less than 140 mm Hg. The data collected showcased 765 and 828 primary outcome events in intensive and standard treatment groups, respectively. Consequently, it confirmed intensive SBP treatment’s potential in reducing the risk of MCI or dementia. Digging deeper into the data, certain trends emerged. Older age, Medicare enrollment, and higher baseline serum creatinine levels correlated with a higher risk of the primary outcome. Conversely, enhanced baseline cognitive functioning and active employment status signified lower risk. Interestingly, higher baseline risk connected directly with greater […]

Adding to the evidence that good nutrition supports healthy aging, this study shows that blood levels of certain saturated fatty acids, along with omega-6, -7 and -9 fatty acids, correlated with improved memory as well as larger frontal, temporal, parietal lobes.

Two-hundred sixteen (216) people with mild-to-moderate disease were treated with 100 mg simufilam tablets twice daily for 12 months. ADAS-Cog-11 score showed a “highly desirable” overall minimal decline in cognitive ability after one year. Simufilam is an oral small molecule designed to to prevent beta and tau amyloid clumping by correctong an altered form of filamin A.

Top-line data from an open-label Phase 2 study of 216 people with mild-to-moderate Alzheimer’s disease treated with simufilam tablets at 100 mg twice daily for a year revealed a minimal decline in cognitive ability overall, as measured by the Alzheimer’s Disease Assessment Scale-Cognitive Subscale (ADAS-Cog-11). Simufilam was found to be safe and well tolerated, and it alleviated depression and dementia-related behaviors in patients, which were two exploratory trial goals.